Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Chimeric Drug Design with a Noncharged Carrier for Mitochondrial Delivery

Version 1 : Received: 13 December 2020 / Approved: 15 December 2020 / Online: 15 December 2020 (08:35:30 CET)

A peer-reviewed article of this Preprint also exists.

Ripoll, C.; Herrero-Foncubierta, P.; Puente-Muñoz, V.; Gonzalez-Garcia, M.C.; Miguel, D.; Resa, S.; Paredes, J.M.; Ruedas-Rama, M.J.; Garcia-Fernandez, E.; Martin, M.; Roldan, M.; Rocha, S.; De Keersmaecker, H.; Hofkens, J.; Cuerva, J.M.; Orte, A. Chimeric Drug Design with a Noncharged Carrier for Mitochondrial Delivery. Pharmaceutics 2021, 13, 254. Ripoll, C.; Herrero-Foncubierta, P.; Puente-Muñoz, V.; Gonzalez-Garcia, M.C.; Miguel, D.; Resa, S.; Paredes, J.M.; Ruedas-Rama, M.J.; Garcia-Fernandez, E.; Martin, M.; Roldan, M.; Rocha, S.; De Keersmaecker, H.; Hofkens, J.; Cuerva, J.M.; Orte, A. Chimeric Drug Design with a Noncharged Carrier for Mitochondrial Delivery. Pharmaceutics 2021, 13, 254.

Journal reference: Pharmaceutics 2021, 13, 254
DOI: 10.3390/pharmaceutics13020254

Abstract

Recently, it was proposed that the thiophene ring is capable of promoting mitochondrial accumulation when linked to fluorescent markers. As a noncharged group, thiophene presents several advantages from a synthetic point of view, making it easier to incorporate such a side moiety into different molecules. Herein, we confirm the general applicability of thiophene group as mitochondrial carrier for drugs and fluorescent markers, based on a new concept of nonprotonable, noncharged transporters. We implemented this concept in a medicinal chemistry application by developing an anti-tumoral, metabolic chimeric drug, based on PDHK inhibitor dichloroacetate (DCA). The promising features of the thiophene moiety as a noncharged carrier for targeting mitochondria may represent a starting point for the design of new metabolism-aimed drugs.

Subject Areas

Antitumor agents; Fluorescence lifetime imaging; Medicinal chemistry; Metabolic drug; Mitochondrial carrier

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.